Trading Signals: TNXP Stock Price Prediction and Forecast (Fri. Feb. 3, 2012 - Fri. May. 13, 2022)(Tonix Pharmaceuticals)
| TNXP latest price $2050.0000 (5.67%) ($1868.5000 - $2180.0000) on Tue. Jun. 21, 2016. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 5.8% (three month average) | RSI | 42 | Latest Price | $2050.0000(5.67%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TNXP declines -4.4% a day on average for past five trading days. | Weekly Trend | TNXP declines -11.4% a week on average for past two weeks. | Market Behavior | Broad based sell-off for large cap. Growth stock sell-off for small cap. | Correlated ETFs | Broad market will support TNXP advance at 0% a week (0% probability) IWO(13%) ARKG(12%) IBB(12%) IWC(12%) IWM(12%) | Factors Impacting TNXP price | TNXP will decline at least -2.9% in a week (0% probabilities). GLD(-6%) BWX(-6%) VIXM(-5%) TLT(-5%) SIL(-5%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -2.9% (StdDev 5.8%) | Hourly BBV | 0 () | Intraday Trend | 4.6% | | | |
|
Resistance Level | $2390.45 | 5 Day Moving Average | $2078(-1.35%) | 10 Day Moving Average | $2297.05(-10.76%) | 20 Day Moving Average | $2390.45(-14.24%) | To recent high | -29.3% | To recent low | 5.7% | Market Cap | $543.25b | | | | Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company. It focuses on discovering and developing small molecules and biologics to treat psychiatric, pain and addiction conditions, to improve biodefense through potential medical counter-measures, to treat transplant rejection and to treat gastric and pancreatic cancers. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and Tonmya. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in New York, NY.July 16, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced it has entered into a research collaboration and option agreement with Columbia University focused on studying the immune responses to COVID-19 in healthy volunteers who have recovered from COVID-19 or were asymptomatic. The research collaboration will focus on T cell and antibody responses to SARS-CoV-2 (CoV-2), the virus that causes COVID-19 at the cellular level including human monoclonal antibodies and anti-idiotypes. The research is designed to fill in important gaps in understanding the detailed immune responses to COVID-19, and to provide a foundation upon which to target vaccines and therapeutics to appropriate individuals by precision medicine. |